Following NCPE assessment of the company submission, omalizumab (Xolair ®) is not considered cost-effective for the treatment of severe allergic asthma and therefore is not recommended for reimbursement.
Reimbursement Not Recommended at the submitted price.
Reimbursement recommended for certain subgroups
The NCPE does not recommend reimbursement of Insulin Degludec (Tresiba®) for Type 1 and 2 Diabetes mellitus at the submitted price.
The NCPE does not recommend reimbursement of Obinutuzumab (Gazyvaro®) in combination with chlorambucil for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.
The NCPE recommends reimbursement of simeprevir in combination with sofosbuvir for the treatment of chronic hepatitis C genotype 1 in some subgroups
The NCPE does not recommend the reimbursement of Pomalidomide for the treatment of Refractory or Relapsed and Refractory Multiple Myeloma at the submitted price.
Vacancy for a health technology assessor with the NCPE
The NCPE finds dimethyl fumarate (Tecfidera®) not cost-effective for the treatment of adult patients with relapsing remitting MS and therefore does not recommend reimbursement at the submitted price
The NCPE Review Group concludes that, at the current price, pregabalin (Lyrica®) is not cost effective as a first line treatment for generalised anxiety disorder.